Arrivent Biopharma, INC. (AVBP) — 10-Q Filings

10-Q Filings (6)

• ArriVent's R&D Surge Drives 118% Net Loss Increase to $130.8M — Nov 10, 2025 Risk: high
  ArriVent BioPharma, Inc. (AVBP) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $130.8 million, up from $59.9
• ArriVent's Losses Widen Amid R&D Surge, Bolstered by $172.5M Offering — Aug 11, 2025 Risk: medium
  ArriVent BioPharma, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company experience
• ArriVent BioPharma Files Q1 2025 10-Q — May 12, 2025 Risk: low
  ArriVent BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial da
• ArriVent BioPharma Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  ArriVent BioPharma, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third
• ArriVent BioPharma Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  ArriVent BioPharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business ope
• ArriVent BioPharma Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: low
  ArriVent BioPharma, Inc. (AVBP) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. ArriVent BioPharma, Inc. filed a 10-Q report for the quarter ended

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX